This bill inserts a new Section 524C into the Federal Food, Drug, and Cosmetic Act to create a mechanism for "reciprocal marketing approval." Sponsors can ask the FDA to deem a drug, biological product, or device—already authorized for sale in specified foreign jurisdictions or the United Kingdom—as having U.S. approval or clearance if certain eligibility checks are met.
The statute sets a tight 30‑day clock for the agency to grant or deny a request, requires translated foreign dossiers, treats a granted reciprocal approval as equivalent to conventional FDA approval/clearance for most statutory purposes (including user fees), and gives Congress a path to overturn an FDA denial so that approval can take effect. The bill emphasizes speed and access for products tied to public health or unmet medical needs while leaving the agency authority to require postmarket studies or to deny approval on safety or effectiveness grounds.
At a Glance
What It Does
Creates a new statutory pathway that deems certain foreign‑authorized drugs, biologics, and devices as approved or cleared in the U.S. if the sponsor requests it and the product meets specified eligibility criteria. It mandates a 30‑day decision window, permits conditions such as postmarket studies, and treats requests as fee‑bearing applications.
Who It Affects
Manufacturers whose products are authorized in countries listed under section 802(b)(1) or the United Kingdom, FDA review staff, hospitals and clinicians seeking products for unmet medical needs, and payers that cover these products. Congress and federal committees gain an expedited reporting and disapproval mechanism.
Why It Matters
The bill shifts emphasis from independent, full premarket review toward regulatory reliance on foreign authorizations, potentially accelerating U.S. access but increasing the agency's postmarket monitoring burden and exposing approval decisions to expedited Congressional override.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill authorizes sponsors to request that the FDA treat a product already lawfully marketed abroad as if it had an existing U.S. approval or clearance. To be eligible, the product must be authorized in one or more countries on a specified list or in the United Kingdom, not already approved in the United States, not subject to prior safety‑related withdrawals, not a banned device, and address a public health or unmet medical need.
The sponsor must provide an English translation of the foreign regulatory dossier for each relevant country.
Once the agency receives a request, it has 30 days to issue an order granting or denying reciprocal marketing approval. The agency can refuse approval if it affirmatively finds the product is not safe and effective (for drugs) or lacks a reasonable assurance of safety and effectiveness (for devices).
If approval is granted, the product is treated, for statutory purposes, the same way as products approved under existing FDA pathways—this affects labeling obligations, postmarket requirements, and fees.The bill also builds a procedural overlay that makes denials visible to Congress: the FDA must list and transmit monthly denial reports to two Appropriations/oversight committees. Congress can enact a joint resolution that, if passed, prevents the Secretary’s denial from taking effect and causes reciprocal approval to take effect upon enactment.
During the 30‑day window the agency and sponsor must finalize U.S. labeling, and the agency must classify devices and determine whether the device would otherwise require premarket notification or approval.Finally, the statute allows the FDA to condition approvals on postmarket studies, including risk‑mitigation strategies, treats requests as subject to user fees under FDA’s fee statutes, and requires the agency to conduct outreach to potentially eligible sponsors. The statutory text leaves considerable discretion to the Secretary on implementation details—what materials suffice, what constitutes adequate evidence of unmet need, and how to structure any required postmarket obligations—while creating hard deadlines and a Congressional check that can effectively reverse an agency denial.
The Five Things You Need to Know
The FDA must grant or deny a reciprocal marketing approval request within 30 days of receipt; decisions are effective subject to Congressional disapproval rules.
Eligibility requires lawful marketing authorization in one or more countries on the unspecified list under section 802(b)(1) or in the United Kingdom, and submission of English translations of each foreign regulatory dossier relied upon.
The Secretary may deny approval on affirmative safety/effectiveness grounds and must compile and transmit a monthly list of denials to the House Energy and Commerce Committee and the Senate HELP Committee.
A granted reciprocal marketing approval is treated as if the product had an active approval/clearance under section 505(c), 510(k), 515, or section 351(a) of the PHS Act, and requests are fee‑bearing under FDA’s chapter VII user fee provisions.
Congress can overturn an FDA denial via a joint resolution of disapproval; enactment of such a resolution prevents the Secretary’s denial from taking effect and causes reciprocal approval to take effect upon enactment.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Deemed equivalence to approved/cleared applications
This subsection creates the core legal effect: once reciprocal marketing approval is in effect for a ‘‘covered product,’’ that product is treated as if it were the subject of an approved or cleared application under existing statutory pathways (drug NDA/ANDA/BLA, device 510(k)/PMA). Practically, that means statutory obligations and benefits tied to approval—labeling, reporting, and applicability of FDA authorities—apply to these products the same as to conventionally reviewed products.
Eligibility criteria sponsors must meet
The bill lays out a checklist: a sponsor must request approval and prove the product is lawfully marketed in one or more specified foreign jurisdictions (or the UK); it must not already be approved in the U.S.; there must be no withdrawal of authorizations abroad or by FDA for safety/effectiveness reasons; devices must not be banned; and the product must address a public health or unmet medical need. Each element creates a gate that can be disputed in practice—especially the ‘‘public health or unmet medical need’’ standard, which the Secretary will define through case‑by‑case determinations.
Safety review, conditioning, and reporting of denials
Subsection (c) preserves a safety backstop: the Secretary can deny a request if, on affirmative finding, the product lacks safety/effectiveness. The agency may also require postmarket studies or risk‑mitigation strategies as conditions of approval. Importantly, the bill compels transparency by requiring the FDA to list denials monthly and send that list to two congressional committees—creating routine oversight and public visibility of cases the agency rejects.
Submission requirements, 30‑day clock, labeling and device classification
Sponsors must submit materials in a form specified by FDA and include English translations of foreign dossiers. The agency then has 30 days to act; during that window the sponsor and FDA must finalize U.S. labeling and the agency must classify any device and decide whether, absent reciprocity, it would require 510(k) clearance or PMA approval. Those concurrent tasks compress both substantive review and administrative tasks into a short timeframe, putting pressure on FDA resources and on the completeness of sponsor submissions.
Congressional disapproval procedure, statutory applicability, and fees
If the Secretary declines to grant approval, Congress can pursue a joint resolution of disapproval modeled on procedural provisions of 5 U.S.C. § 802. The text is structured so that enactment of such a resolution prevents the agency’s denial from taking effect and causes the reciprocal approval to take effect. The bill also clarifies that all existing provisions of the FD&C Act apply to reciprocally approved products and treats requests as equivalent to fee‑bearing applications under the user‑fee chapter—shifting costs and integrating the pathway into FDA’s financial and regulatory framework.
Agency outreach and definition of covered product
The Secretary is required to conduct outreach to encourage eligible sponsors to apply, signaling a policy intent to actively solicit foreign‑authorized products. The statute defines ‘‘covered product’’ broadly to include drugs, biological products, and devices, so the pathway is not limited by product class beyond the substantive eligibility rules earlier in the section.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with unmet medical needs — They could gain faster access to treatments already marketed abroad when no U.S. alternative exists, because the pathway expedites market entry.
- Foreign manufacturers and sponsors — Companies whose products are authorized in the listed foreign jurisdictions or the UK gain a faster, more predictable route into the U.S. market with reduced need for full duplicate premarket packages.
- U.S. clinicians and hospitals — Health systems treating conditions with few options may obtain and use additional therapies or devices sooner under U.S. law, improving treatment choices.
- Sponsors with limited FDA experience — Smaller or non‑U.S. firms that have navigated other regulators can leverage that work to seek U.S. access without repeating every regulatory step.
- Regulatory harmonization advocates — Entities pushing for greater reliance on foreign regulatory decisions gain a statutory mechanism to operationalize that policy preference.
Who Bears the Cost
- FDA and taxpayers — The 30‑day deadline, translation requirements, and outreach obligation will increase workload and demand staffing and systems; treating requests as fee‑bearing helps but may not fully cover implementation costs.
- Domestic manufacturers — U.S. firms could face faster competition from products approved abroad, potentially altering market dynamics and pricing for niche or orphan products.
- Patients and payers (conditional) — If premarket review is truncated in practice, downstream safety events could impose clinical and financial costs on healthcare systems and insurers, who may bear the immediate treatment costs.
- Congressional oversight committees and staff — The monthly denial reporting and potential frequent use of the joint resolution mechanism will impose legislative workload and could politicize individual product decisions.
- Healthcare providers — Clinicians and hospitals may need to absorb new labeling, training, and monitoring obligations for products whose premarket evidence differs from traditional FDA packages.
Key Issues
The Core Tension
The central dilemma is whether to prioritize rapid access to potentially lifesaving products by relying on foreign authorizations, or to preserve the FDA’s independent, often more demanding U.S. premarket assessment to safeguard against safety and effectiveness risks—especially when Congressional override can convert an agency denial into an effective approval.
The bill creates a fast lane that relies heavily on foreign regulatory decisions combined with a compressed FDA review window and an unusually strong congressional backstop. That raises several implementation questions: what standard of review will the Secretary apply within 30 days, how complete must foreign dossiers be to satisfy FDA’s documentation needs, and how will the agency manage translation and technical review logistics without diverting resources from other review programs?
The statutory text leaves significant discretionary space to the Secretary, but the 30‑day mandate and Congressional disapproval option could incentivize more automatic approvals or shallow denials to avoid political conflict.
There are trade‑offs between earlier patient access and the integrity of the U.S. premarket standard. Conditioning approvals on postmarket studies is one mitigation, but postmarket obligations historically face compliance, data quality, and enforcement gaps.
The Congressional disapproval mechanism flips the usual dynamic by allowing Congress to force approval despite an agency safety judgment, creating a risk of politicizing product safety decisions. Finally, treating requests as fee‑bearing integrates them into FDA’s funding model but may shift internal priorities and does not resolve the additional inspection, compliance, and surveillance costs that could follow accelerated entry of foreign‑authorized products.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.